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Available online 6 April 2016Background: Protease-Activated Receptor-1 (PAR-1) plays an important role in the pathogenesis of multiplema-
lignancies and its expression strongly also affects the outcomes of cancer patients. The objective of this studywas
to determine the clinical signiﬁcance of the serum levels of PAR-1in cutaneous melanoma patients.
Methods: A total of 60 patients with a pathologically conﬁrmed diagnosis of cutaneous melanoma were enrolled
into this study. Serum PAR-1concentrations were determined by the solid-phase sandwich ELISA method.
Results: No signiﬁcant difference in serum PAR-1 levels between melanoma patients and healthy controls was
found (p = 0.07). The known clinical variables including age of patient, gender, site of lesion, histology, stage
of disease, serum LDH levels and chemotherapy responsiveness were not correlated with serum PAR-1 concen-
trations (p N 0.05). Likewise, serum PAR-1 concentration had also no prognostic role on survival (p = 0.41).
Conclusion: Serum levels of PAR-1 have no diagnostic, predictive and prognostic roles in cutaneous melanoma
patients.
General signiﬁcance: Measurement of PAR-1 in serum is not a clinical signiﬁcance in cutaneous melanoma
patients.
© 2016 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Protease Activated Receptor-1 (PAR-1), the prototypic member of
the PAR family, is activated by thrombin following cleavage of its extra-
cellular amino terminus domain [1]. PAR-1 and its activating factors,
which are expressed on tumor cells and the surrounding stroma, induce
not only coagulation, but also play an important role in promoting can-
cer progression in several malignancies such as lung, breast, prostate
and melanoma [1].
Melanoma displays multifactorial etiology and its genetic and im-
munological background has not yet been fully elucidated. In vitro trials
showed that cultured melanoma cell lines produce excessive levels of
cytokines and growth factors with pleiotropic biological activities.
Among them, PAR-1 functions as an autocrine and paracrine factor
that drives many cellular processes such as tumor growth, invasion, an-
giogenesis and metastasis [1]. Increased expression and secretion of
PAR-1 isoform inmelanoma cells has been documented by several trials
when compared with normal melanocytes [1–4]. Cell activation of the
PAR-1 pathway in melanoma cell lines has been well documented. In-
creased expression of PAR-1 was found as closely associated with mel-
anoma progression and metastasis in many various studies [1–10].anbul University, Capa, 34390,
pen access article under the CC BY-NAlthough almost all available ﬁndings were provided from preclini-
cal trials, so far, no clinical study to investigate the clinical signiﬁcance
of PAR-1 isoform in plasma/serum in melanoma patients. Thus, the sig-
niﬁcance of the serological levels of PAR-1in melanoma patients is not
known yet. Therefore, we evaluated the soluble serum levels of PAR-1
in melanoma patients, and assessed associations with the prognosis,
various known clinical variables, and response to chemotherapy, in
order to examine whether these are potential new biomarkers, for use
in the treatment of melanoma in this study.
2. Material and methods
2.1. Patients
This study comprised 60 patients admitted to Istanbul University, In-
stitute of Oncology with histologically conﬁrmed cutaneousmelanoma.
Patients with bidimensionally measurable disease without history of
chemo/radiotherapy in the last six months were included in the study.
The stagingwas determined according to the American Joint Committee
on Cancer (AJCC) staging system. The pretreatment evaluation included
detailed clinical history and physical examination with a series of bio-
chemistry tests including LDH and complete blood cell counts. Those
with ECOG performance status ≤2 and appropriate blood chemistry
tests received chemotherapy on outpatient basis comprising interferon
alpha, cisplatin, dacarbazine or temozolomide compounds with/C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Patient and disease characteristics.
Variables n
No. of patients 60
Age, years
b50/≥50 26/34
Gender
Male/female 33/27
Site of lesion
Axial/extremity/unknown 38/16/6
Histology
Nodular/nonnodular/unknown 9/31/20
Stage of disease
I–II/III/IV/unknown 13/14/31/2
Tumor statusa
Thin (T1–2)/thick (T3–4)/unknown 10/16/1
Node statusa
Negative/positive 12/14
M1 status
M1a + b/M1c 13/18
Serum hemoglobin level (12 g/dL)
Low/normal/unknown 19/40/1
SerumWhite blood cell (WBC) count (10000)
Normal/elevated/unknown 50/9/1
Serum LDH level (450 U/L)
Normal/elevated 48/12
Erythrocyte sedimentation rate (ESR) (40/h)
Normal/elevated/unknown 28/20/12
Response to chemotherapyb
Yes/no/unknown 10/11/10
Last status
Alive/dead 41/19
a In nonmetastatic patients.
b Metastatic patients.
Table 2
The values of serum PAR-1 levels in melanoma patients and healthy controls.
Assay Patients (n = 60) Controls (n = 30) p
Median Range Median Range
PAR-1(ng/mL) 0.052 0.00–6.110 0.079 0.030–0.230 0.07
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grams consisted of clinical, laboratory, radiological assessments per-
formed at 8 week intervals during chemotherapy or every 12 weeks
for no anticancer treatment. Response to treatmentwas determined ac-
cording to revised RECIST criteria version 1.1.
For comparison of serum levels of PAR-1, age and sex matched 30
healthy controls were included in the analysis. Written informed con-
sent was obtained from the patients and this study was approved by
our ethical committee.
2.2. Measurement of serum PAR-1 levels
Serum samples were obtained on ﬁrst admission before any adju-
vant and metastatic treatment was given or follow-up patients. Blood
samples were obtained from patients with malignant melanoma and
healthy controls by venipuncture and clotted at room temperature.
The serawere collected following centrifugation and frozen immediate-
ly at−20 °C until analysis.
The Human Protease Activated Receptor 1 (PAR-1) ELISA (Wuhan
EIAab Science, China) uses a double-antibody sandwich enzyme-
linked immunosorbent assay to determine the level of Human PAR-1
in samples. Serum samples and standards were added to the wells
which were pre-coated with Human PAR-1 monoclonal antibody and
allowed to incubate for 2 h. Unbound material was washed away and
PAR-1 combined with Streptavidin-HRP were added to form immune
complex and then allowed to incubate for 1 h. Unbound material was
washed away. Chromogen solution was added and incubated for 15–
25 min (protect from light) for the conversion of the colorless solution
to a blue solution, the intensity of which was proportional to the
amount of PAR-1 in the sample. As the effect of the acidic stop solution,
the color has become yellow. The colored reaction product was mea-
sured using an automated ELISA reader (Rayto, RT-1904C Chemistry
Analyzer, Atlanta, GA, USA) at 450 nm. The results were expressed as
ng/mL.
2.3. Statistical analysis
Continuous variables were categorized using median values as cut-
off point. Assessment of relationships, comparisons between various
clinical/laboratory parameters and serum levels of PAR-1 assaywere ac-
complished using Mann–Whitney U test. Survival was calculated from
the date of ﬁrst admission to hospital to death resulting from any
cause or to last contact with the patient or any family member.
Kaplan–Meier method was used for estimation of survival of patient
and differences in survivals were assessed by the log-rank statistics. A
p value ≤0.05was considered signiﬁcant. Statistical analysis was carried
out using SPSS 16.0 software.
3. Results
A total of 60 cutaneous melanoma patients enrolled into this study.
The baseline histopathological and the demographic characteristics of
the patients are listed in Table 1. The median age at diagnosis was
53.5 years, range 16–88 years.
There was no signiﬁcant difference in serum PAR-1 levels between
melanoma patients and healthy controls (p = 0.07) (Table 2). The
known clinical variables including age of patient, gender, site of lesion,
histology, stage of disease, serum LDH levels and chemotherapy respon-
siveness were not correlated with serum PAR-1 concentrations
(p N 0.05) (Table 3).
The median follow-up time was 11.1 months (range 6–39 months).
Themedian survival for all patients was 26.0months (%95 CI= 21–30).
The 1-, 2-, and 3-year overall survival rates were 76.3% (%95 CI = 64–
88), 55.6% (%95 CI= 39–72), and 51.0% (%95 CI= 33–69), respectively.
As expected, the presence of metastasis (p b 0.001), advancedmetasta-
tic disease (M1c) (p= 0.007), elevated erythrocyte sedimentation rate(p b 0.001), higher serum LDH levels (p b 0.001), and unresponsiveness
to chemotherapy (p = 0.01) had statistically signiﬁcant worse survival
(Table 3). However, serum PAR-1 concentration was not associated
with outcome (p = 0.41) (Table 3 and Fig. 1).
4. Discussion
Tissue microarray trials showed that PAR-1 was highly expressed in
melanoma as compared to melanocytic nevi and normal skin [1]. More-
over, a signiﬁcantly elevated PAR-1 expression level in clinical samples
of atypical nevi andmelanoma compared tomelanocytic nevi [2]. In ad-
dition to these trials, PAR-1 expression correlated with their metastatic
potential in melanoma cell lines [3,4]. PAR-1 regulates melanoma cell
growth andmetastasis by affecting both invasive and angiogenic factors
because of displaying decreased blood vessel density [3]. These factors
can act in both an autocrine and paracrine fashion, inﬂuencing both
melanoma tumor cells, as well as cells in the tumor microenvironment
[1,3].
Tumor and stromal interactions are backbone to melanoma growth
and metastasis [1]. PAR-1 is not only expressed on melanoma cells but
is also expressed on several cell types in the melanoma microenviron-
ment, such as endothelial cells, platelets, ﬁbroblasts and macrophages.
Activation of PAR-1 in melanoma cells results in secretion of cytokines,
expression of adhesion molecules and increased vascular permeability
in multiple steps during melanoma carcinogenesis, including prolifera-
tion, angiogenesis, invasion, and survival [1]. In the past years, signiﬁ-
cant research efforts have focused on determining the role of PAR-1 in
Table 3
Distribution and survival comparisons of serum PAR-1 levels on various clinical parame-
ters in melanoma patients.
Parameter Serum PAR-1 level
p value
Distribution Survival
Age, years 0.91 0.20
b50/≥50
Gender 0.82 0.35
Male/female
Site of lesion 0.68 0.35
Axial/extremity
Histology 0.32 0.50
Nodular/others
Tumor status (in M0 disease) 0.24 0.61
T1–2/T3–4
Node status (in M0 disease) 0.16 0.48
Negative/positive
Metastasis status 0.23 b0.001
Yes/no
M1 status 0.65 0.007
M1a-b/M1c
Erythrocyte sedimentation rate 0.67 b0.001
Normal/elevated
Serum LDH level 0.90 b0.001
Normal/elevated
Response to chemotherapy 0.81 0.01
No yes
Serum PAR-1 level – 0.41
bmedian/≥median
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ing molecules [1]. A link between PAR-1 and platelet activating factor
receptor (PAFR) was established [5]. Moreover, two genes that are reg-
ulated by PAR-1, connexin 43 and maspin, both involved in modulating
the interactions between melanoma cells and the stroma [6,7]. Thus,
PAR-1 is both essential in promoting cross-talk betweenmetastaticmel-
anoma cells and themicroenvironment and important in transcription-
ally regulating various genes involved in the metastatic process in
melanoma [1]. PAR-1 also plays a signiﬁcant role in promotingmelano-
ma cell migration, motility, antiapoptotic behavior, and survival [1,8].
Moreover, overexpression of PAR-1 also promotes metastaticFig. 1. Survival curves in melanoma patients acmelanoma as it can function as a growth factor [1]. Activation of PAR-
1 by MMP-1 in melanoma cells has been shown to induce the expres-
sion of growth factors, aswell as promote the invasiveness ofmelanoma
cells [1,9].
Targeting PAR-1 utilizing siRNA incorporated DOPC liposomes
inhibited melanoma tumor growth, metastases and angiogenesis in
nude mice [3]. Thus, decreased melanoma growth and metastasis can
be achieved directly by inhibiting PAR-1 on melanoma cells, indirectly
by inhibiting PAR-1 activity on platelets [1,3,10]. Taken together, these
data suggest that PAR-1 could be a potential therapeutic target for met-
astatic melanoma.
Although all available ﬁndings were provided from preclinical trials
using melanoma tissue sections, so far, no clinical study to investigate
the clinical signiﬁcance of PAR-1 isoform in serum or plasma inmelano-
ma patients. Thus, the signiﬁcance of the serological levels of PAR-1 in
melanoma patients is not known yet. A total of 60 patients with differ-
ent stages of melanoma were studied in this study. Serum PAR-1 con-
centrations were determined by the solid-phase sandwich ELISA
method. The results demonstrated that the analysis of serum PAR-1
was not able to discriminate between the melanoma patients and
healthy persons, indicating that PAR-1 was not a good serological diag-
nosticmarker ofmelanomapatients. Likewise, therewere no signiﬁcant
associations between serum PAR-1 levels and clinical characteristics in-
cluding age of patient, gender, site of lesion, histology, stage of disease,
and serum LDH level. Similarly, no link between serum PAR-1 concen-
trations and chemosensitivity has raised the possibility of using PAR-1
as predictors of response to chemotherapy in patients scheduled to un-
dergo various chemotherapeutic regimens in our study. We showed
that serum PAR-1 levels may not be a potential predictor of clinical re-
sponse to chemotherapy in melanoma patients. Moreover, we also
found that serum levels of PAR-1 were not associated with survival.
Therefore, in this study, PAR-1 concentrations in serum could not be
useful prognostic marker to predict tumor prognosis in melanoma pa-
tients. Overall, it means that these ﬁndings are inconsistent with the
aforementioned data provided from preclinical studies. Furthermore,
we have also previously reported similar observations in patients with
epithelial ovarian carcinoma including small sample number (n = 44)
using a different ELISA kit [11]. In this trial, we found that serum PAR-
1 levels were signiﬁcantly elevated in patients compared with healthycording to serum PAR-1 levels (p = 0.41).
169F. Tas et al. / BBA Clinical 5 (2016) 166–169controls, whereas any clinical variables including chemotherapy re-
sponsiveness and survival did not associate with the serum PAR-1
assay. In our newly published studywhich consists of gastric cancer pa-
tients, identical results were also determined using same ELISA kit used
in the current study [12].
In conclusion, we showed that serum levels of PAR-1 have no diag-
nostic, predictive and prognostic roles in melanoma patients. However,
the small sample size and short follow-up time of our study could be
considered as signiﬁcant limitation andmight have inﬂuenced these re-
sults. However, our study contributes to the literature, because we per-
formed preliminarily in literature. Further studies in a larger patient
population are necessary to determine the potential clinical signiﬁcance
of these assays in melanoma.
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